Stock Analiz

Biogen Inc. (BIIB) stock forecast and price target

Price $253.40 · data as of November 13, 2026

12-month price target

Average target$268.26
Upside / downside+5.9%
Analysts32
ConsensusBuy
Low $175.00Average $268.26High $350.00

Gold marker: average target · white marker: today’s price ($253.40)

Analyst ratings

Strong buy 4Buy 21Hold 10Sell 1Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$12.53−18.0%$10.6B
Next fiscal year
ends December 31, 2027
$16.26+29.7%$10.8B
Next quarter
ends December 31, 2026
$2.82+41.9%$2.6B
Quarter after
ends March 31, 2027
$3.57+0.1%$2.6B

Consensus of the analysts covering Biogen, updated daily. In the last 30 days 13 estimates were raised and 14 lowered.

Our model vs. Wall Street

Analysts see 5.9% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Biogen’s intrinsic value about 33% below today’s market value, and it scores 1.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Biogen stock price target?

The average 12-month target from 32 analysts is $268.26, 5.9% above the current price of $253.40 Targets range from $175.00 to $350.00.

Is Biogen a buy according to analysts?

The consensus rating is “Buy” (4 strong buy, 21 buy, 10 hold, 1 sell). Ratings are opinions, not guarantees; this is not investment advice.

How much is Biogen expected to earn?

Analysts expect EPS of $12.53 for the fiscal year ending December 31, 2026 and $16.26 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.